The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Minocycline Provides Neuroprotection Against N-Methyl-d-aspartate Neurotoxicity by Inhibiting Microglia
Abstract
Glutamate excitotoxicity to a large extent is mediated through activation of the N-methyl-d-aspartate (NMDA)-gated ion channels in several neurodegenerative diseases and ischemic stroke. Minocycline, a tetracycline derivative with antiinflammatory effects, inhibits IL-1β-converting enzyme and inducible nitric oxide synthase up-regulation in animal models of ischemic stroke and Huntington’s disease and is therapeutic in these disease animal models. Here we report that nanomolar concentrations of minocycline protect neurons in mixed spinal cord cultures against NMDA excitotoxicity. NMDA treatment alone induced microglial proliferation, which preceded neuronal death, and administration of extra microglial cells on top of these cultures enhanced the NMDA neurotoxicity. Minocycline inhibited all these responses to NMDA. Minocycline also prevented the NMDA-induced proliferation of microglial cells and the increased release of IL-1β and nitric oxide in pure microglia cultures. Finally, minocycline inhibited the NMDA-induced activation of p38 mitogen-activated protein kinase (MAPK) in microglial cells, and a specific p38 MAPK inhibitor, but not a p44/42 MAPK inhibitor, reduced the NMDA toxicity. Together, these results suggest that microglial activation contributes to NMDA excitotoxicity and that minocycline, a tetracycline derivative, represents a potential therapeutic agent for brain diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Pathobiology of ischaemic stroke: an integrated view
Dirnagl, U., Iadecola, C., & Moskowitz, M. A. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01401-0 · Cited by 3,943
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Keys, J. R., Land vatter, S. W., et al. (1994) · Nature · doi:10.1038/372739a0 · Cited by 3,288
Activated microglia mediate neuronal cell injury via a nitric oxide mechanism
Chao, C. C., Hu, S., Molitor, T. W., Shaskan, E. G., & Peterson, P. K. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.8.2736 · Cited by 1,136
The changing landscape of ischaemic brain injury mechanisms
Lee, J.-M., Zipfel, G. J., & Choi, D. W. (1999) · Nature · doi:10.1038/399a007 · Cited by 1,102 · cited 2×
“Because inflammation is a delayed and prolonged response to brain injury, it is regarded as atempting pharmacological target with a potentially wide therapeutic window, unlike NMDAR antagonists that must be delivered immediately after a brain insult and have strong side effects (2, 22, 23).”
BackgroundChen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K. B., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,051
Yrjänheikki, J., Tikka, T., Keinänen, R., Goldsteins, G., Chan, P. H., & Koistinaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,038
Self-citationTetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 2×
“Considering the neuroprotection achieved with minocycline in animal models of stroke (24, 25) and Huntington’s disease (26), our cell culture findings suggest that minocycline may represent a potential therapeutic agent for treatment of brain diseases which involve excitotoxicity.”
BackgroundHara, H., Friedlander, R. M., Gagliardini, V., Ayata, C., Fink, K., Huang, Z., Shimizu-Sasamata, M., Yuan, J., & Moskowitz, M. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2007 · Cited by 834
Bhat, N. R., Zhang, P., Lee, J. C., & Hogan, E. L. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-05-01633.1998 · Cited by 713
Cited by
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
“…demonstrated in vitro (Tikka et al., 2001b) and in other experimental models of acute and chronic brain insults (Yrjanheikki et al., 1998, 1999; Tikka and Koistinaho, 2001; Tikka et al., 2001a) and results, presumably, from the blockade of p38 mitogen-activated protein kinase (Tikka et al.,…”
BackgroundInfluentialRole of Pro-Inflammatory Cytokines Released from Microglia in Neurodegenerative Diseases
Smith, J. A., Das, A., Ray, S. K., & Banik, N. L. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.10.004 · Cited by 1,165
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
“…production of IL-1 and NO, has been shown to inhibit p38 MAPK as well as poly(ADP-ribose) polymerase-1, which along with inhibition of NF-kB (see below), may serve as the basis for its anti-inflammatory efficacy (Tikka et al, 2001; Tikka and Koistinaho, 2001; Si et al, 2004; Alano et al, 2006).”
BackgroundApoptosis and Caspases in Neurodegenerative Diseases
Friedlander, R. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022366 · Cited by 873
Traumatic Brain Injuries: Pathophysiology and Potential Therapeutic Targets
Ng, S. Y., & Lee, A. Y. W. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00528 · Cited by 852
Raghavendra, V., Tanga, F., & DeLeo, J. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.052407 · Cited by 797
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789
Obesity and neuroinflammation: A pathway to cognitive impairment
Miller, A. A., & Spencer, S. J. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.04.001 · Cited by 788
Role of Microglia in Central Nervous System Infections
Rock, R. B., Gekker, G., Hu, S., Sheng, W. S., Cheeran, M., Lokensgard, J. R., & Peterson, P. K. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.4.942-964.2004 · Cited by 723
Molecular targets in cerebral ischemia for developing novel therapeutics
Mehta, S. L., Manhas, N., & Raghubir, R. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.11.003 · Cited by 708
Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
Petzold, A. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.015 · Cited by 688
Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission
Pascual, O., Ben Achour, S., Rostaing, P., Triller, A., & Bessis, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111098109 · Cited by 693
Ledeboer, A., Sloane, E. M., Milligan, E. D., Frank, M. G., Mahony, J. H., Maier, S. F., & Watkins, L. R. (2005) · Pain · doi:10.1016/j.pain.2005.02.009 · Cited by 677
GLIA: A novel drug discovery target for clinical pain
Watkins, L. R., & Maier, S. F. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1251 · Cited by 672
The Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
The microbiome: a key regulator of stress and neuroinflammation
Rea, K., Dinan, T. G., & Cryan, J. F. (2016) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.03.001 · Cited by 508
Stirling, D. P., Khodarahmi, K., Liu, J., McPhail, L. T., McBride, C. B., Steeves, J. D., Ramer, M. S., & Tetzlaff, W. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5275-03.2004 · Cited by 507
Microglia Biology in Health and Disease
Garden, G. A., & Möller, T. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9015-5 · Cited by 496
Microglial control of neuronal death and synaptic properties
Bessis, A., Béchade, C., Bernard, D., & Roumier, A. (2007) · Glia · doi:10.1002/glia.20459 · Cited by 452
Minocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
Microglial activation in presymptomatic Huntington's disease gene carriers
Tai, Y. F., Pavese, N., Gerhard, A., Tabrizi, S. J., Barker, R. A., Brooks, D. J., & Piccini, P. (2007) · Brain · doi:10.1093/brain/awm044 · Cited by 440
Minocycline treatment in acute stroke: An open-label, evaluator-blinded study
Lampl, Y., Boaz, M., Gilad, R., Lorberboym, M., Dabby, R., Rapoport, A., Anca-Hershkowitz, M., & Sadeh, M. (2007) · Neurology · doi:10.1212/01.wnl.0000277487.04281.db · Cited by 440
Nakazawa, T., Nakazawa, C., Matsubara, A., Noda, K., Hisatomi, T., She, H., Michaud, N., Hafezi-Moghadam, A., Miller, J. W., & Benowitz, L. I. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2801-06.2006 · Cited by 436
Targeting leukocyte MMPs and transmigration
Brundula, V., Rewcastle, N. B., Metz, L. M., Bernard, C. C., & Yong, V. W. (2002) · Brain · doi:10.1093/brain/awf133 · Cited by 426
Microglial Activation in Stroke: Therapeutic Targets
Yenari, M. A., Kauppinen, T. M., & Swanson, R. A. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.005 · Cited by 389
Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease
Lee Mosley, R., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K., Laurie, C., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 387
Verge, G. M., Milligan, E. D., Maier, S. F., Watkins, L. R., Naeve, G. S., & Foster, A. C. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03593.x · Cited by 386
Cell Signaling and the Genesis of Neuropathic Pain
Ji, R.-R., & Strichartz, G. (2004) · Science's STKE · doi:10.1126/stke.2522004re14 · Cited by 371
Yenari, M. A., Xu, L., Tang, X. N., Qiao, Y., & Giffard, R. G. (2006) · Stroke · doi:10.1161/01.str.0000206281.77178.ac · Cited by 359
Neuroinflammation after intracerebral hemorrhage
Mracsko, E., & Veltkamp, R. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00388 · Cited by 344
Teng, Y. D., Choi, H., Onario, R. C., Zhu, S., Desilets, F. C., Lan, S., Woodard, E. J., Snyder, E. Y., Eichler, M. E., & Friedlander, R. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306239101 · Cited by 335
Watkins, L. R., Hutchinson, M. R., Ledeboer, A., Wieseler-Frank, J., Milligan, E. D., & Maier, S. F. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.10.011 · Cited by 326
Kraus, R. L., Pasieczny, R., Lariosa‐Willingham, K., Turner, M. S., Jiang, A., & Trauger, J. W. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03219.x · Cited by 321
Fine, P. G. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01187.x · Cited by 314
Lee, S. M., Yune, T. Y., Kim, S. J., Park, D. W., Lee, Y. K., Kim, Y. C., Oh, Y. J., Markelonis, G. J., & Oh, T. H. (2003) · Journal of Neurotrauma · doi:10.1089/089771503770195867 · Cited by 305
The influence of microglia on the pathogenesis of Parkinson's disease
Long-Smith, C. M., Sullivan, A. M., & Nolan, Y. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.08.001 · Cited by 296
Inhibition of autoimmune encephalomyelitis by a tetracycline
Popovic, N., Schubart, A., Goetz, B. D., Zhang, S., Linington, C., & Duncan, I. D. (2002) · Annals of Neurology · doi:10.1002/ana.10092 · Cited by 295
“Minocycline prevents the death of cultured neurons exposed to glutamate, kainic acid, or N-methyl-D-aspartate.7,29 Glutamate antagonists were recently shown to lessen disease in EAE models and to be neuroprotective.30,31 Stimulation of glutamate receptors is thought to cause microglial proliferation with subsequent gl…”
BackgroundMika, J., Osikowicz, M., Makuch, W., & Przewlocka, B. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.01.013 · Cited by 290
Inflammation, Glutamate, and Glia in Depression:A Literature Review
McNally, L., Bhagwagar, Z., & Hannestad, J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016734 · Cited by 289
Milligan, E. D., Zapata, V., Chacur, M., Schoeniger, D., Biedenkapp, J., O'Connor, K. A., Verge, G. M., Chapman, G., Green, P., Foster, A. C., et al. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03709.x · Cited by 289
Role of p38 and p44/42 mitogen‐activated protein kinases in microglia
Koistinaho, M., & Koistinaho, J. (2002) · Glia · doi:10.1002/glia.10151 · Cited by 281
Self-citationMinocycline as a Neuroprotective Agent
Stirling, D. P., Koochesfahani, K. M., Steeves, J. D., & Tetzlaff, W. (2005) · The Neuroscientist · doi:10.1177/1073858405275175 · Cited by 279
Yune, T. Y., Lee, J. Y., Jung, G. Y., Kim, S. J., Jiang, M. H., Kim, Y. C., Oh, Y. J., Markelonis, G. J., & Oh, T. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1661-07.2007 · Cited by 270
Glial activation and pathological pain
Wieseler-Frank, J., Maier, S. F., & Watkins, L. R. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2003.09.009 · Cited by 265
Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment
Ravina, B. M., Fagan, S. C., Hart, R. G., Hovinga, C. A., Murphy, D. D., Dawson, T. M., & Marler, J. R. (2003) · Neurology · doi:10.1212/01.wnl.0000058760.13152.1a · Cited by 262
Hawryluk, G. W. J., Rowland, J., Kwon, B. K., & Fehlings, M. G. (2008) · Neurosurgical Focus · doi:10.3171/foc.2008.25.11.e14 · Cited by 252
Sriram, K., Miller, D. B., & O'Callaghan, J. P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03566.x · Cited by 242
Role of transcription factors in mediating post-ischemic cerebral inflammation and brain damage
YI, J., PARK, S., KAPADIA, R., & VEMUGANTI, R. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.019 · Cited by 206
Central Proinflammatory Cytokines and Pain Enhancement
Wieseler-Frank, J., Maier, S. F., & Watkins, L. R. (2005) · Neurosignals · doi:10.1159/000087655 · Cited by 198
Watkins, L. R., Hutchinson, M. R., Milligan, E. D., & Maier, S. F. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.06.006 · Cited by 185
TNF-α knockout and minocycline treatment attenuates blood–brain barrier leakage in MPTP-treated mice
Zhao, C., Ling, Z., Newman, M. B., Bhatia, A., & Carvey, P. M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.012 · Cited by 183
Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162
Clinical Potential of Minocycline for Neurodegenerative Disorders
BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157
Amyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications
Cozzolino, M., Ferri, A., & Teresa Carrì, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1760 · Cited by 156
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146
The Potential of Minocycline for Neuroprotection in Human Neurologic Disease
Zemke, D., & Majid, A. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000150867.98887.3e · Cited by 125
Koistinaho, M., Malm, T. M., Kettunen, M. I., Goldsteins, G., Starckx, S., Kauppinen, R. A., Opdenakker, G., & Koistinaho, J. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600040 · Cited by 120
The microglia in healthy and diseased retina
Li, L., Eter, N., & Heiduschka, P. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.04.020 · Cited by 112
Tikka, T., Usenius, T., Tenhunen, M., Keinänen, R., & Koistinaho, J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00543.x · Cited by 96
Self-citationThe Therapeutic Role of Minocycline in Parkinson’s Disease
Cankaya, S., Cankaya, B., Kilic, U., Kilic, E., & Yulug, B. (2019) · Drugs in Context · doi:10.7573/dic.212553 · Cited by 93
Ryu, J. K., Choi, H. B., & McLarnon, J. G. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.04.010 · Cited by 93
Role of Inflammation in Depression: Implications for Phenomenology, Pathophysiology and Treatment
Raison, C. L., & Miller, A. H. (2013) · Modern Trends in Psychiatry · doi:10.1159/000343966 · Cited by 88
Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Chen, Y., Won, S. J., Xu, Y., & Swanson, R. A. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666131228203906 · Cited by 81
Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate?
Buller, K. M., Carty, M. L., Reinebrant, H. E., & Wixey, J. A. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21890 · Cited by 73
Thomas, M., Le, W. D., & Jankovic, J. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200301000-00005 · Cited by 62
Ryu, J. K., Kim, S. U., & McLarnon, J. G. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.006 · Cited by 62
Neuroendocrine-Immune Crosstalk Shapes Sex-Specific Brain Development
Arambula, S. E., & McCarthy, M. M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa055 · Cited by 55
Baptiste, D. C., Hartwick, A. T. E., Jollimore, C. A. B., Baldridge, W. H., Seigel, G. M., & Kelly, M. E. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001081 · Cited by 55
Stress-Activated Protein Kinases in Spinal Cord Injury: Focus on Roles of p38
Kasuya, Y., Umezawa, H., & Hatano, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030867 · Cited by 54
Izumi, Y., Cashikar, A. G., Krishnan, K., Paul, S. M., Covey, D. F., Mennerick, S. J., & Zorumski, C. F. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1502-21.2021 · Cited by 53
Defaux, A., Zurich, M.-G., Honegger, P., & Monnet-Tschudi, F. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.04.053 · Cited by 40
Metadata
- Authors
- Tikka, T. M., & Koistinaho, J. E.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-06
- Volume
- 166
- Issue
- 12
- Pages
- 7527-7533
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2158230836
- Cited by
- 530
- References
- 54
- FWCI
- 13.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.